"Compulsory licensing of pharmaceutical patents" means that in an emergency or for public health purposes, a small amount of patent transfer fee can be paid for patented drugs without the consent of the patentee, and the government grants and permits other enterprises to use a patent.
In fact, India is not the only country in the world with compulsory licenses and generic drugs, and South Africa has had a similar experience. In the face of the severe AIDS epidemic in 1999, the South African government promulgated an amendment to the Law on the Administration of Drugs and Related Products, introducing a "compulsory license" system, but it was sued by pharmaceutical companies. Under the pressure of the international community, multinational pharmaceutical companies finally decided to drop the lawsuit. "Paying attention to life can transcend respect for patent rights" finally became an important conclusion of this case, which also contributed to the adjustment of a series of international rules such as WTO.
In 2003, the General Council of the WTO adopted a resolution on the implementation of paragraph 6 of the Doha Declaration, clarifying that developing members and least developed members can implement a compulsory licensing system for the production, sale and use of patented products without the consent of the patentee in case of public health crisis, such as AIDS, malaria, tuberculosis and other epidemic diseases.